Investing.com - LAVA Therapeutics NV reported on Tuesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
LAVA Therapeutics NV announced earnings per share of $-0.31 on revenue of $468K. Analysts polled by Investing.com EPS of $-0.6002 on revenue of $500K.
LAVA Therapeutics NV 's are down 72% and is trading at $2.46 , still down 70.64% from its 52 week high of $8.38 set on Wednesday, October 13, 2021.
LAVA Therapeutics NV follows other major Healthcare sector earnings this month
LAVA Therapeutics NV's report follows an earnings beat by Medtronic on Tuesday, August 23, 2022, who reported EPS of $1.13 on revenue of $7.37B, EPS of $1.12 on revenue of $7.22B.
Merck ADR had beat expectations on Friday with third quarter EPS of $0.5392 on revenue of $5.69B, for EPS of $0.5165 on revenue of $5.57B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar